Our approach expands patient populations beyond those eligible for SSTR2-only radioligand and peptide medical treatments.
Increasing anti-tumoral activity through dual SSTR2 and SSTR5 agonism both in radioligand and in chronic medical therapy
Our novel radioligand and linker promise improved pharmacokinetics and biodistribution for alpha and beta therapy
In laboratory models of NETs, our lead drug candidate reduced neuroendocrine tumor cell growth more than today’s standard drugs in several tests.
Our dual SSTR2/SSTR5 agonists deliver potent anti-hormonal and antiproliferative effects in pituitary and pancreatic NET models at low nanomolar doses.
These results are preclinical, but they support moving SMTR-002 into further studies to see if it can offer NET patients a more effective, longer-lasting treatment option that addresses a major unmet need.
MD PhD, Founder & CEO
MD PhD, Co-Founder
MD, Principal Medical Advisor
Grafton Therapeutics is excited to share our newly published study in Frontiers in Oncology showing how our novel dual SSTR2/SSTR5 agonists are pushing the boundaries of what’s possible.
